| Title |
Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
|
|---|---|
| Published in |
BMC Cancer, October 2014
|
| DOI | 10.1186/1471-2407-14-779 |
| Pubmed ID | |
| Authors |
Daniel Castellano, Javier Puente, Guillermo de Velasco, Isabel Chirivella, Pilar López-Criado, Nicolás Mohedano, Ovidio Fernández, Icíar García-Carbonero, María Belén González, Enrique Grande |
| Abstract |
Patients with transitional cell carcinoma of the urothelial tract (TCCU) who fail initial platinum-based chemotherapy for advanced disease represent a challenge in daily clinical practice. Vinflunine is approved by the European Medicine Agency (EMA) but, up to now, limited experience has been reported outside clinical trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 13% |
| Student > Master | 6 | 13% |
| Researcher | 5 | 11% |
| Student > Ph. D. Student | 5 | 11% |
| Other | 4 | 9% |
| Other | 3 | 6% |
| Unknown | 18 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 34% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Nursing and Health Professions | 3 | 6% |
| Mathematics | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 18 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2014.
All research outputs
#17,735,364
of 22,775,504 outputs
Outputs from BMC Cancer
#4,956
of 8,286 outputs
Outputs of similar age
#175,903
of 260,977 outputs
Outputs of similar age from BMC Cancer
#112
of 179 outputs
Altmetric has tracked 22,775,504 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,286 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,977 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.